Arcoma

Arcoma LT Debt/Equity

Long-Term Debt to Equity Ratio of Arcoma (ARCOMA.ST) as of Oct 27, 2026.

LT Debt/Equity

0.00

Last updated:

Long-Term Debt to Equity Ratio of Arcoma is 2025 0.00 . Long-Term Debt to Equity Ratio of Arcoma was 2024 0.00 . It decreases by % lower compared to the previous year.

The Arcoma LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.02 SEK
Jan 1, 2019
0.01 SEK
Jan 1, 2020
0.05 SEK
Jan 1, 2021
0.04 SEK
Jan 1, 2022
0.08 SEK
Jan 1, 2023
0.04 SEK
Jan 1, 2024
0.00 SEK
Jan 1, 2025
0.00 SEK
The Arcoma LT Debt/Equity history
YEARLT Debt/EquityYoY
0.00—
0.00-100.00%
0.04-53.09%
0.08+104.96%
0.04-19.74%
0.05+694.18%
0.01-68.15%
0.02-33.72%
0.03-34.67%
0.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Arcoma since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Arcoma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Arcoma

All Key Metrics — Arcoma